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Abstract: Human hepatocellular carcinoma (HCC) is associated
with elevated expressions of inducible nitric oxide synthase (iNOS)
but the role of nitric oxide in the pathogenesis of HCC remains
unknown. We found that the abundance and activity of S-nitrosoglu-
tathione reductase (GSNOR), a protein critical for control of protein
S-nitrosylation, was signiﬁcantly decreased in approximately 50%
of patients with HCC. GSNOR-deﬁcient mice were very susceptible
to spontaneous and carcinogen-induced HCC. During inﬂammatory
responses, the livers of GSNOR-deﬁcient mice exhibited substantial
S-nitrosylation and proteasomal degradation of the key DNA repair
protein, O(6)-alkylguanine-DNA alkyltransferase. As a result, repair
of carcinogenic O(6)-alkylguanines in GSNOR-deﬁcient mice was sig-
niﬁcantly impaired. Predisposition to HCC, S-nitrosylation and deple-
tion of alkylguanine-DNA alkyltransferase, and accumulation of
O(6)-alkylguanines were all abolished in mice deﬁcient in both
GSNOR and iNOS. Thus, our data suggest that GSNOR deﬁciency,
through dysregulated S-nitrosylation, may promote HCC, possibly
by inactivating a DNA repair system.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Hepatocellular carcinoma is comprised of a heterogeneous group
of tumors [1]. Complex transcriptomic analyses have led to the
molecular classiﬁcation of hepatocellular tumors into several
subtypes [2–4]. The multiplicity of tumor subtypes renders the
development of treatment strategies especially challenging
because the molecules that can be targeted by drugs will differ
according to the subtype. In fact, there are few target molecules
active in the pathogenesis of HCC that are shared among tumor
subtypes. mTOR is one targetable molecule that is shared byJournal of Hepatology 20
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E-mail address: jf.dufour@ikp.unibe.ch (J.-F. Dufour).many HCC subtypes; it is inhibited by sirolimus and everolimus
and is active in almost half of all HCCs studied [5]. Another inter-
esting target molecule is Ras, which phosphorylates Raf, the tar-
get of sorafenib, and is active in the majority of HCCs [6]. As a
possible addition to this short list, Limin Liu and co-workers have
uncovered a new carcinogenic pathway with therapeutic
potential.
S-nitroso-glutathione (GSNO) is a metabolite, which is formed
by the nitrosylation of GSH by nitric oxide (NO) in the presence of
oxygen and metabolized by GSNO reductase (GSNOR). GSNO acts
as a NO donor, a reservoir of nitrosyl residues capable of forming
proteins adducts. Nitrosylation of Cys residues in proteins serves
a post-translational regulatory function in many processes,
including the inactivation of the DNA repair enzyme, O6-alkyl-
guanine-DNA alkyltransferase (AGT). O6-alkylguanine can pair
with a thymidine rather than a cytosine and yields G:C to A:T
transitions. Liu and colleagues probed the relationship between
the tumorigenesis of HCC, the levels of NO, and the S-nitrosyla-
tion of AGT. Their experiments were designed to ask whether
GSNOR was an inﬂuential player in liver tumorigenesis.
Liu et al. previously generated mice that harbor a targeted
deletion of GSNOR. GNSOR/ mice accumulate S-nitrosothiols
and have increased levels of protein S-nitrosylation [7]. Liu now
reports that GNSOR/ mice have a 10-fold higher incidence of
spontaneous liver tumors than controls. In an effort to elucidate
the mechanisms involved, they generated mice deﬁcient in both
GNSOR/ and inducible nitric oxide synthase (iNOS/) and
demonstrated that the accumulation of nitroso-compounds,
which are mutagenic by virtue of the increased production of
O6-alkylguanines, is a critical step. GNSOR//iNOS/ mice pro-
duced much less nitroso-compounds but were no more suscepti-
ble to the development of spontaneous or chemically-induced
(diethylnitrosamine) liver tumors than wild-type mice. In diet-
hylnitrosamine treated GNSOR/ mice, the activity of AGT was
massively decreased whereas in GNSOR//iNOS/ mice, AGT
activity did not change. Decreased AGT was associated with
diminished DNA repair, which was assessed by measuring O6-
ethyl dG six days after challenge with diethylnitrosamine. Fur-
thermore, after exposure to LPS to induce iNOS, the level of S-nit-
rosylated AGT, which represents inactivated AGT, was equally
low in GSNOR/ and controls, absent in GSNOR//iNOS/ but
was rescued by a proteasome inhibitor in GSNOR/ only. Finally,
Liu examined tissues of 24 patients with HCC and showed the
activity of GSNOR to be 80–90% lower than in the adjacent non
tumoral tissue in 10 patients. This lower GSNOR activity11 vol. 54 j 579–580
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Fig. 1. Inﬂammation induces the expression of iNOS, which results in an
increased production of nitric oxide and nitrosoglutathione (GSNO). GSNO is
degraded by a reductase, GSNOR. GSNO is in equilibrium with nitrosylated
proteins, among them the DNA repair enzyme AGT, which is then degraded by the
proteasome. Nitroso compounds lead to the formation of O6-alkylguanines,
which, if not repaired by AGT, will cause mutagenesis and favour the tumorigenic
processes and hepatocellular carcinoma.
International Hepatologycorrelated well with a decreased expression of the protein. In
these same tissues the expression of AGT was also diminished
(Fig. 1).
These data open up perspectives for therapeutic applications.
In HCC, inducible NOS is frequently activated and nitrite/nitrate
levels elevated. This raises the question of the suitability of iNOS
as a target molecule. Notwithstanding the genetic approach cho-
sen by Liu et al. the treatment of GSNOR/ mice with an iNOS
inhibitor would have been equally as informative. Further to their
observation that the level of nitrosylated AGT is degraded by the
proteasome, a remaining question is whether proteasome
inhibitors could not only rescue the protein level but also the
enzymatic DNA repair activity and protect against the carcinogen-
esis process inGNSOR/mice. Proteasome inhibitors have already
proven beneﬁcial in oncology (bortezomide, Velcade). An even
more intriguing question is whether a selective defect of DNA
repair in hepatic tumors could be advantageous. Are these tumors
amenable to treatmentwith alkylating agents? Such a strategy has
had some success in treating glioblastomas. The expression of AGT
is frequently silenced in glioblastomas due to promoter methyla-
tion, with the result that some glioblastomas are particularly sus-
ceptible to the alkylating drug, temozolomide [8].
Notwithstanding the important new information delivered in
this paper, a few weaknesses stand out. The small number of
human HCC samples (24) precludes a ﬁrm conclusion regarding
the prevalence of altered GSNOR expression in the HCC patient580 Journal of Hepatology 201population. The concurrent determination of iNOS in these sam-
ples should have been presented. Other important targets of S-
nitrosylation, in addition to AGT should have been mentioned.
The mechanism by which GSNOR is down-regulated is not
addressed in humans. The authors only speculate about a gene
deletion in region 4q23, a region of frequent chromosomal dele-
tions, or genetic/epigenetic defects. The control experiment con-
ﬁrming the absence of iNOS in the double knockout model is
missing as is immunohistochemistry evidence of GNSOR and
AGT deﬁciency in mouse and human livers. Finally, there is no
demonstration of O6-ethyl dG in human samples.
Despite these omissions, this work sheds new light on a liver
carcinogenic pathway that may be relevant to a majority of
patients. The next step should therefore be to focus on identifying
those patients whose tumors depend on abnormal S-nitrosothiol
metabolism by measuring circulating nitrite/nitrate levels and
offer them speciﬁc pharmacological intervention accordingly.Conﬂict of interest
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